New targeted therapies in pancreatic cancer

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer

(2016) Shubham Pant et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO

(2014) Philip A. Philip et al.   CANCER

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)

(2014) T. Dragovich et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells

(2014) M R Moniri et al.   CANCER GENE THERAPY

Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis

(2014) Masanori Kobayashi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model

(2014) Christian Bauer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells

(2014) He Ren et al.   CANCER LETTERS

Hypoxia-Inducible Factor-1 Promotes Pancreatic Ductal Adenocarcinoma Invasion and Metastasis by Activating Transcription of the Actin-Bundling Protein Fascin

(2014) X. Zhao et al.   CANCER RESEARCH

A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer

(2014) D.J. Renouf et al.   EUROPEAN JOURNAL OF CANCER

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

(2014) Jeffrey R. Infante et al.   EUROPEAN JOURNAL OF CANCER

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study

(2014) D.J. Watkins et al.   EUROPEAN JOURNAL OF CANCER

Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells

(2014) Qingshan Pei et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival

(2014) Alessandra De Remigis et al.   INTERNATIONAL JOURNAL OF CANCER

Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer

(2014) E. Gabriela Chiorean et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

(2014) Ana De Jesus-Acosta et al.   INVESTIGATIONAL NEW DRUGS

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

(2014) Neil Desai et al.   Translational Oncology

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer

(2014) Jae Yun Lim et al.   Cancer Research and Treatment

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

(2013) O. E. Rahma et al.   ANNALS OF ONCOLOGY

Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)

(2013) H. Fensterer et al.   ANNALS OF ONCOLOGY

Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo

(2013) Deniz A. Ucar et al.   Anti-Cancer Agents in Medicinal Chemistry

Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

(2013) Nikolaos Ioannou et al.   BMC CANCER

IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer

(2013) Toshiki Hirakawa et al.   BMC CANCER

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

(2013) R Alvarez et al.   BRITISH JOURNAL OF CANCER

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer

(2013) Shinichi Yabuuchi et al.   CANCER LETTERS

Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma

(2013) A. Avan et al.   CANCER RESEARCH

Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor

(2013) I. McCaffery et al.   CLINICAL CANCER RESEARCH

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

(2013) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

(2013) Amir Avan et al.   CURRENT PHARMACEUTICAL DESIGN

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

(2013) Stefano Cascinu et al.   DIGESTIVE AND LIVER DISEASE

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

(2013) Philippe Rougier et al.   EUROPEAN JOURNAL OF CANCER

Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy

(2013) Zahary Raykov et al.   INTERNATIONAL JOURNAL OF CANCER

Phase 2 Study of Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy in Patients With Resectable Pancreatic Cancer

(2013) Joseph M. Herman et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

(2013) Stefan Boeck et al.   JOURNAL OF GASTROENTEROLOGY

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

(2013) Dung T. Le et al.   JOURNAL OF IMMUNOTHERAPY

The quest to overcome resistance to EGFR-targeted therapies in cancer

(2013) Curtis R Chong et al.   NATURE MEDICINE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis

(2013) Wei Tian et al.   PANCREATOLOGY

Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2

(2013) R. Maron et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

(2013) C Hage et al.   Cell Death & Disease

A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer

(2012) Peter J. Hosein et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

(2012) H. L. Kindler et al.   ANNALS OF ONCOLOGY

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

(2012) A. Gonçalves et al.   ANNALS OF ONCOLOGY

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

(2012) S Boeck et al.   BRITISH JOURNAL OF CANCER

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

(2012) J Harder et al.   BRITISH JOURNAL OF CANCER

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

(2012) Christine M. Ardito et al.   CANCER CELL

EGFR and HER2 inhibition in pancreatic cancer

(2012) Naomi Walsh et al.   INVESTIGATIONAL NEW DRUGS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment

(2012) Bin Bao et al.   PLoS One

Prognostic MicroRNAs in Cancer Tissue from Patients Operated for Pancreatic Cancer—Five MicroRNAs in a Prognostic Index

(2012) Nicolai A. Schultz et al.   WORLD JOURNAL OF SURGERY

nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer

(2012) Kristopher K. Frese et al.   Cancer Discovery

A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

(2011) Lutz Eric et al.   ANNALS OF SURGERY

Bcl-2 Upregulation Induced by miR-21 Via a Direct Interaction Is Associated with Apoptosis and Chemoresistance in MIA PaCa-2 Pancreatic Cancer Cells

(2011) Jie Dong et al.   ARCHIVES OF MEDICAL RESEARCH

hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes

(2011) Else M. Inderberg Suso et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells

(2011) Victoria Sung et al.   CANCER SCIENCE

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

(2011) Yefei Rong et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway

(2011) Sonyo Shin-Kang et al.   FREE RADICAL BIOLOGY AND MEDICINE

c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target

(2011) Chenwei Li et al.   GASTROENTEROLOGY

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

(2011) György Bodoky et al.   INVESTIGATIONAL NEW DRUGS

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

(2011) Hedy L Kindler et al.   LANCET ONCOLOGY

Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer

(2011) J. Taeger et al.   MOLECULAR CANCER THERAPEUTICS

Effects and Mechanisms of the Combination of Suberoylanilide Hydroxamic Acid and Bortezomib on the Anticancer Property of Gemcitabine in Pancreatic Cancer

(2011) Jun Kyu Lee et al.   PANCREAS

Clinical and Immunologic Evaluation of Dendritic Cell–Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma

(2011) Yukino Kimura et al.   PANCREAS

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine

(2010) Ghassan K. Abou-Alfa et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

(2010) Milind M Javle et al.   BMC CANCER

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer

(2010) Gilda da Cunha Santos et al.   CANCER

Nanoparticulate delivery of diphtheria toxin DNA effectively kills mesothelin expressing pancreatic cancer cells

(2010) SL Showalter et al.   CANCER BIOLOGY & THERAPY

MicroRNA miR-155 is a biomarker of early pancreatic neoplasia

(2010) Nils Habbe et al.   CANCER BIOLOGY & THERAPY

Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer

(2010) J. Feliu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

(2010) Andrew H. Ko et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model

(2010) Hidenobu Ishizaki et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer

(2010) S. Yu et al.   CANCER RESEARCH

miR-146a Suppresses Invasion of Pancreatic Cancer Cells

(2010) Y. Li et al.   CANCER RESEARCH

The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS

(2010) Wu-Gan Zhao et al.   CARCINOGENESIS

Mesenchymal stromal cells alone or expressing interferon-β suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment

(2010) Shannon Kidd et al.   CYTOTHERAPY

MicroRNA-20a Overexpression Inhibited Proliferation and Metastasis of Pancreatic Carcinoma Cells

(2010) Haijiao Yan et al.   HUMAN GENE THERAPY

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

(2010) Synne Wedén et al.   INTERNATIONAL JOURNAL OF CANCER

MicroRNA-196: critical roles and clinical applications in development and cancer

(2010) Changyi Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Radiation-Induced DNA Repair and Prosurvival Pathways Contributes to Vorinostat-Mediated Radiosensitization of Pancreatic Cancer Cells

(2010) Amit Deorukhkar et al.   PANCREAS

Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer

(2010) Jin-Hyeok Hwang et al.   PLoS One

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

(2009) Motoki Miyazawa et al.   CANCER SCIENCE

Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies

(2009) M. Campoli et al.   CLINICAL CANCER RESEARCH

Notch Signaling: The Core Pathway and Its Posttranslational Regulation

(2009) Mark E. Fortini   DEVELOPMENTAL CELL

let-7 MicroRNA Transfer in Pancreatic Cancer-Derived Cells Inhibits In Vitro Cell Proliferation but Fails to Alter Tumor Progression

(2009) Jérôme Torrisani et al.   HUMAN GENE THERAPY

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

(2009) Donald A. Richards et al.   INVESTIGATIONAL NEW DRUGS

Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors

(2009) Radharani Gollamudi et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411

(2009) Christopher H. Crane et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance

(2009) T. Moriyama et al.   MOLECULAR CANCER THERAPEUTICS

The Hedgehog Pathway and Pancreatic Cancer

(2009) Manuel Hidalgo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

(2009) Joanna M. Brell et al.   ONCOLOGY

A Combination Therapy of Gemcitabine With Immunotherapy for Patients With Inoperable Locally Advanced Pancreatic Cancer

(2009) Yoshiki Hirooka et al.   PANCREAS

Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma

(2009) Jong-Kook Park et al.   PANCREAS

MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells

(2009) Qing Ji et al.   PLoS One

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers

(2009) M. Seike et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

(2008) D. Laheru et al.   CLINICAL CANCER RESEARCH

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival

(2008) Mary Dillhoff et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

(2008) Jean-Philippe Spano et al.   LANCET

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE

Hyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cells

(2008) Bryan P. Toole et al.   SEMINARS IN CANCER BIOLOGY